Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

pany's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the belief that Anadys is well-positioned to create value in the evolving HCV landscape; (ii) Anadys' objective to extend the favorable results seen last year when ANA598 was dosed over 12 weeks with the recently initiated Phase IIb study; (iii) the belief that the ANA598 Phase IIb study should set the stage for Phase III development; (iv) the ability for patients to achieve SVR24 in the ANA598 Phase IIb study; (v) the timing, occurrence and outcome of expected milestone events; and (vi) the plans and expected trial design for advancing ANA773 in development for HCV.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its abil
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... (PRWEB) April 23, 2015 The ... intends to conduct a groundbreaking pilot study to ... be reversed in as little as three to ... of metabolic and nutritional medicine—will aggressively target and ... and destroy our aging brain. These include oxidative ...
(Date:4/23/2015)... Six startups from Russia traveled to ... part of the U.S.-Russia Innovation Corridor (USRIC) program. ... startups to participate in the program since the ... University of Maryland (UMD) signed a Memorandum of ... in the biomedical industry in 2013. , Supported ...
(Date:4/23/2015)... April 23, 2015 Follow ... to a series of genetic tests that determine ... Lou Gehrig's disease, Huntington's disease, and Alzheimer's disease. ... gene composition and interaction in diseased tissue/cells to ... well as the response to treatment, such as ...
(Date:4/23/2015)... -- Prospects for Leading Companies in OTC, ...   We predict the global healthcare packaging ... 2015 and will grow at a CAGR of 6.3% between ... the world and increasing functional requirements for healthcare packaging products ... healthcare packaging market. A global ageing population, changing ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10
... National Institute of Standards and Technology (NIST), in ... (NASA), has published detailed guidelines* for making essential ... The new guide constitutes the current best practices ... heavily studied of the new generation of nanoscale ...
... Mr. Glynn has over 34 years of,combined financial, ... the life sciences industry for his role in the ... Glynn,retired from Invitrogen Corporation (Nasdaq: IVGN ) in ... several operating roles including CFO,President and COO and CEO. ...
... shows naturally occurring antibodies contained in, GAMMAGARD ... Alzheimer,s disease, CHICAGO, April 15 The ... Inc. (NYSE: BAX ) today,announced data from ... LIQUID [Immune Globulin Intravenous (Human)] (IGIV),marketed as KIOVIG ...
Cached Biology Technology:Carbon nanotube measurements: latest in NIST 'how-to' series 2eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... leftovers. A research study appearing in the April 2009 ... ( http://www.jleukbio.org ) sheds light on one cause of ... States and The Netherlands show that a specific gene ... leftover remnants of bacteria cell walls, called muramyl dipeptide ...
... San Diego, CA (March 31, 2009) Novocell, Inc., ... has received U.S. Patent 7,510,876 with claims covering human ... only pancreatic type cells, which Novocell is developing for ... other endoderm lineage-derived tissues and organs such as lungs, ...
... University master,s graduate is working with doctors at Vanderbilt ... microscope that could someday reduce the number of biopsies ... the skin often prompt dermatologists to remove skin samples ... to diagnose skin cancers, said Chris Arrasmith, who recently ...
Cached Biology News:Bad mix of bacterial remnants and genetics leads to arthritis 2Montana State grad's work helps diagnose skin cancer without a biopsy 2Montana State grad's work helps diagnose skin cancer without a biopsy 3
... Sphingobeads are designed for ... and characterize sphingosine binding proteins. ... 1 mL of agarose beads ... bound through the terminus of ...
... PolarScreen Androgen Receptor (AR) Competitor Assay Kits ... studying and screening potential AR ligands using ... AR ligand binding domain protein tagged with ... novel, selective fluorescent androgen ligand (Fluormone AL ...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... proteomic scale kinase profiling, quantitative measurement ... discovery research built on the flexible ... platform. These microarrays are available as ... Substrate - Peptide Microarray Service. ...
Biology Products: